---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-153923"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:22:28.069356+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corbus completes enrollment in CANYON-1 Phase 1b trial of CRB-913 for obesity; on track for summer 2026 data

## Summary
- Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913, a peripherally restricted oral CB1 inverse agonist.
- Trial is a 16-week, placebo-controlled, dose-ranging study (n=240) with 20, 40, and 60 mg QD cohorts; completion expected summer 2026.
- Phase 1a data showed 2.9% placebo-adjusted weight loss at Day 14 in obese cohort, with no vomiting, constipation, or nausea reported.
- Neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7) were negative across all cohorts.

## SEC filing metadata
- accession: 0001193125-26-153923
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/0001193125-26-153923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/crbp-20260414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-153923
- JSON: https://secwatch.observer/filing/0001193125-26-153923.json
- Plain text: https://secwatch.observer/filing/0001193125-26-153923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.